Ret tyrosine kinase receptor inhibitor (Tyra Biosciences)

N/A

Report date: 2025/03/20 09:39:58
NME

Base Information

Drug NameRet tyrosine kinase receptor inhibitor (Tyra Biosciences)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitors
TargetsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsLung NeoplasmsThyroid Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTyra Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesTyra Biosciences Inc
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsThyroid Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A